David Meyronet

12PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyHaematological tumoursNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 27, 2025
Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases.

Aurelien Maureille, Enora Vauleon, David Meyronet

|Jan 10, 2025
Establishing a living biobank of pediatric high-grade glioma and ependymoma suitable for cancer pharmacology.

Clémence Deligne, Arthur Tourbez, Flavie Bénard

|Dec 28, 2024
Nanopore sequencing as a cutting-edge technology for medulloblastoma classification.

Mathilde Filser, Jacob Torrejon, Kevin Merchadou

|Jun 10, 2024
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.

Ines Esparragosa Vazquez, Marc Sanson, Olivier L Chinot

|May 30, 2024
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.

Alberto Picca, Anna Luisa Di Stefano, Julien Savatovsky

|Aug 02, 2023
Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.

Hermes Paraqindes, Nour-El-Houda Mourksi, Samantha Ballesta

Pageof 2

Frequent Collaborators

6 joint publications

Thiébaud Picart

5 joint publications

François Ducray

5 joint publications

Marc Barritault

3 joint publications

Moncef Berhouma